Resistance in Hematologic Malignancies and Cancer

Author:   Lucia Messingerova, PhD (Slovak Academy of Sciences, Centre of Bioscineces, Institute of Molecular Physiology and Genetics, Bratislava, Slovakia) ,  Albert Breier, PhD (Head of Biochemistry and Microbiology Department, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia)
Publisher:   Elsevier Science Publishing Co Inc
ISBN:  

9780443217906


Pages:   326
Publication Date:   01 November 2024
Format:   Hardback
Availability:   Not yet available   Availability explained
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Our Price $462.00 Quantity:  
Pre-Order

Share |

Resistance in Hematologic Malignancies and Cancer


Add your own review!

Overview

Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research. It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells. By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise

Full Product Details

Author:   Lucia Messingerova, PhD (Slovak Academy of Sciences, Centre of Bioscineces, Institute of Molecular Physiology and Genetics, Bratislava, Slovakia) ,  Albert Breier, PhD (Head of Biochemistry and Microbiology Department, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, Slovakia)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
ISBN:  

9780443217906


ISBN 10:   0443217904
Pages:   326
Publication Date:   01 November 2024
Audience:   Professional and scholarly ,  College/higher education ,  Professional & Vocational ,  Postgraduate, Research & Scholarly
Format:   Hardback
Publisher's Status:   Forthcoming
Availability:   Not yet available   Availability explained
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Table of Contents

1. Drug classification for treatment Hematological Malignancies 2. Reduce drug uptake in development of resistance 3. The Role of Enhanced Drug Efflux in Drug Resistance 4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers. 5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells 6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy 7. Altered cell cycle regulation 8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor 9. Immune system in resistance prediction 10. Mechanisms of resistance of antibody-drug conjugates – obstacles to overcome 11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)

Reviews

Author Information

After completing her studies, Dr. Messingerova started working at the Slovak Technical University, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In her work, she focuses on changes in apoptotic pathways, transport, and metabolism of HMAs in sensitive and resistant AML cell lines. The goal of her team's work is to identify an easily and quickly detectable marker of response to HMA treatment, since it is known that after the failure of this treatment in patients unsuitable for intensive therapy, only the possibility of inclusion in clinical trials or palliative care remains. Albert Breier is Professor at the Faculty of Chemical and Food Technology, Slovak University of Technology, and Chief Research fellow at the Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovak Republic, Chief Research Fellow. He holds a PhD in Biochemistry and is the author of more than 130 scientific publications that were more than 1200 times cited. His research interest is anti-cancer agents

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

lgn

al

Shopping Cart
Your cart is empty
Shopping cart
Mailing List